Key oncologic pathways inhibited by Erinacine A: A perspective for its development as an anticancer molecule - 26/02/23







Abstract |
In the modern era, cancer can be controlled by chemotherapy treatment, and in many situations a stable disease is obtained. The significant clinical success and subsequent commercialization of naturally derived molecules have further encouraged their exploration as adjunctive therapies in cancer management. The purpose of this comprehensive review is to update the anticancer mechanisms triggered by Erinacine A and regulation of signaling pathways potentially involved in its anticancer activity.The results of preclinical research showed that Erinacin A, a therapeutically important biological metabolite isolated from the basidiomycete fungus Hericium erinaceus offers a multitude of possible chemotherapeutic applications by regulating complex signaling pathways as validated by various pharmacological in vitro and in vivo studies. As a result of Erinacin A's action on oncological signaling pathways, it resulted in induction of apoptosis, reduction of proliferation, invasiveness, generation of oxidative stress and cell cycle arrest in cancer cells.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Abbreviation : Bcl-2, Bcl-XL, BDNF, C/EBP, CCRD, CDK, CHOP, CytC, EAHE, FAK, FasL, FasR, GLT1, H3K14, H3K9, IFN-γ, IL, iNOS, JNK, LIMK2, LPS, mTOR, MTUS2, NF-kB, NO, PAK, pAkt, PI3K, RNS, ROCK, ROS, RSM, TLR4, TNF-α, TRAIL, WHO
Keywords : Erinacine A, Cancer signalling pathways, Anticancer mechanisms, Apoptosis
Plan
Vol 160
Article 114332- avril 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?